No description available.

The objective of this study was to investigate the diet-induced metabolic changes that affect the brain tissue of juvenile pigs with NAFLD. This study explored the liver- brain axis and metabolic markers in the frontal cortex (FC) affected by liver damage. 18 male (M) and 20 female (F) Iberian pigs were randomly allocated to 1 of 3 high-fructose high-fat liquid diets (lard, olive oil, and coconut oil) and fed for 10 consecutive weeks. “Healthy” Iberian pigs were fed a eucaloric diet to establish a physiological baseline. Protein precipitation extraction using ultra-performance liquid chromatography-tandem quadrupole mass spectrometry was performed for primary metabolic and bile acid assays on FC samples. Univariate data were analyzed by one-way ANOVA, which included diet as the fixed effect and both replicate and pen nested in the diet as random effects. A more pronounced separation was observed in the PLS-DA between the COC and LAR/OLI diets. LC, C14:0 SM, and kynurenine, all metabolites linked to brain health, showed elevated levels in COC-fed pigs and reduced levels in animals fed OLI. Each of the three diets demonstrated heightened ratios of secondary bile acids to primary bile acids, with OLI-fed pigs showing increased TDCA:CA and TLCA:CA ratios associated with neurodegeneration (MahmoudianDehkordi et al., 2019). In conclusion, results may suggest that LAR could represent a more favorable dietary intervention for promoting brain health in pediatric NAFLD but further research is required.

Indiana University-Purdue University Indianapolis (IUPUI) / Hepatic fibrosis is a cellular repair mechanism that is initiated upon prolonged damage to the liver, resulting in an accumulation of excess extracellular matrix. This eventually leads to the formation of scar tissue, which disrupts the hepatic architecture and causes liver dysfunction. Hepatic stellate cells (HSCs) play a major role in hepatic fibrosis. However, the molecular mechanisms remain incompletely understood. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ or WWTR1), key players of the Hippo pathway, have been implicated in the liver fibrosis, but the HSC-specific functions of YAP and TAZ are largely unclear. Here we have identified Sirtuin 6 (SIRT6), an NAD+ dependent deacetylase, as a key epigenetic regulator in the protection against hepatic fibrosis by suppressing the YAP/TAZ activity. SIRT6 has been previously implicated in the regulation of the canonical transforming growth factor β (TGFβ)-SMAD3 pathway. This study has revealed the significant contribution of the non-canonical pathways including the Hippo pathway to the development of hepatic fibrosis. HSC-specific Sirt6 deficient mice developed severe fibrosis when fed a high-fat-cholesterol-cholate diet compared to their wild-type counterparts. YAP became more active in the SIRT6-deficient HSCs. Expression of the YAP/TAZ downstream genes like CTGF, CYR61 and ANKRD1 were elevated in the SIRT6-deficient HSCs. Biochemical and mutagenic analyses have revealed that SIRT6 deacetylates YAP and TAZ at key lysine residues and reprograms the composition of the TEA domain transcription factor complex to suppress the YAP/TAZ function in the hepatic fibrogenesis.

No description available.

No description available.

The mechanistic target of rapamycin (mTOR) is a key serine/threonine protein kinase that functions in complexes mTORC1 and mTORC2. mTORC1, originally discovered due to its sensitivity towards the mTOR inhibitor rapamycin, responds to extracellular growth factor signaling, WNT signaling, and nutrient abundance via glucose and amino acid-triggered signaling. Downstream effectors of mTORC1 include autophagy, mitochondrial metabolic function, protein synthesis, and ribosome biogenesis. mTORC2, initially discovered as a rapamycin-insensitive complex of mTOR, responds to insulin, growth factor signaling, and inflammatory signaling such as tumor necrosis factor-alpha, with its downstream effectors being Akt, a key serine/threonine kinase that functions in cell division and is frequently dysregulated in many types of cancer, the NFkB pathway, and cytoskeletal reorganization and protein synthesis. Much research has been devoted to mTORC1 signaling, with mTORC2 receiving significantly less attention, despite both complexes’ regulation of key cellular activities and response to rapamycin, as well as to other rapamycin-derived drugs (rapalogs). We have targeted both mTORC1 and mTORC2 for hepatocyte-specific deletion during the gestational period of mice, with the goal of describing mTORC1 and mTORC2 signaling and its perturbation in the adult mouse hepatocyte. Our model has shown that deletion of RAPTOR, the regulatory associated protein of mTOR, and RICTOR, the rapamycin insensitive component of mTOR, in mTORC1 and mTORC2 respectively, leads to widespread effects on the hepatocyte transcriptome. We have found that a subset of genes responds both to Raptor and Rictor knockout, and an analysis of these genes indicates their function in key disorders of the liver, such as non-alcoholic fatty liver disease and hepatocellular carcinoma. Bioinformatic analysis following hepatocyte RNA sequencing of mTORC1 and mTORC2 knockout mice has revealed an unexpected upregulation of genes known to be regulated by these respective complexes. We have also found that cross talk exists between both complexes, in which the knockout of one yields the activation of the other. We have additionally found translationally relevant enrichments following Ingenuity Pathway Analysis (IPA) of RNA sequencing data. These results provide a key mechanistic discovery of mTOR signaling activity, and allow for a better understanding of the potential physiological effects of mTOR inhibition in human patients.

A metformina é uma droga utilizada para tratamento da diabetes tipo 2. O PPAR-α tem um papel central no controle imunometabólico. Portanto, o objetivo do estudo foi avaliar os efeitos imunometabólicos da dieta hiperlipídica (HFD), em camundongos C57BL6 (WT) e knockout para PPAR-α, tratados com metformina. Métodos: Os animais foram submetidos a uma HFD por 12 semanas, nos últimos dez dias de dieta os animais foram tratados com metformina. A oxidação de palmitato no músculo esquelético, As citocinas, no fígado, no tecido adiposo retroperitoneal, em hepatócitos e macrófagos intraperitoneais foram analisados. Resultados: O tratamento aumentou a oxidação de palmitado no músculo, promoveu um efeito anti-inflamatório no tecido adiposo e reverteu à inflamação dos macrófagos. No fígado e nos hepatócitos, a metformina causou um efeito inflamatório. Conclusão: A inflamação hepática foi induzida pelo tratamento e o efeito principal foi a um potencial aumento na inflamação nos hepatócitos. Os macrófagos tiveram uma resposta anti-inflamatória, assim como o tecido adiposo. / Metformin is a drug used to treatment of type 2 diabetes. PPAR-α plays a central role in immunometabolic control. Therefore, the aim of the study was to evaluate the effects of imumnometabolics of high fat diet (HFD) in C57BL6 mice (WT) and knockout for PPAR-α treated with metformin. Methods: The animals were subjected to a HFD for 12 weeks in the last ten days of diet the animals were treated with metformin. The palmitate oxidation in skeletal muscle, cytokines in the liver, in the retroperitoneal adipose tissue, hepatocytes and intraperitoneal macrophages were analyzed. Results: The treatment increased palmitate oxidation in muscle, it has promoted an anti-inflammatory effect in adipose tissue and macrophages to inflammation reversed. In the liver and hepatocytes, metformin caused an inflammatory effect. Conclusion: The liver inflammation was induced, and treatment was a main effect to a potential increase in inflammation in hepatocytes. Macrophages have an anti-inflammatory response, as well as adipose tissue.

L'obésité et les maladies du foie associées (NAFLD) augmentent le risque et la sévérité de l’hépatotoxicité induite par certains xénobiotiques, mais les mécanismes impliqués sont encore mal compris. Pour l'éthanol et le paracétamol (APAP), le rôle du cytochrome P450 2E1 (CYP2E1) hépatique est suspecté car l'activité de cette enzyme est augmentée au cours de ces pathologies dysmétaboliques. Le 1er objectif de notre travail expérimental a été de mettre au point un modèle cellulaire de NAFLD caractérisé non seulement par l'accumulation de triglycérides mais aussi par l’augmentation de l'activité du CYP2E1. Pour cela, des cellules humaines HepaRG différenciées ont été incubées pendant une semaine avec de l'acide stéarique ou de l'acide oléique, en présence de 3 concentrations différentes d'insuline. Les triglycérides cellulaires et l'expression de gènes induits au cours de la stéatose étaient similaires avec les deux acides gras. Cependant, l'activité du CYP2E1 était significativement augmentée uniquement par le stéarate et ceci était associé à une diminution de l'activité du CYP3A4, une autre caractéristique des NAFLD. L’activité du CYP2E1 dans les cellules HepaRG était réduite par l'insuline d'une manière concentration-dépendante et cet effet était reproduit sur des hépatocytes humains en culture primaire. Ainsi, l'activité du CYP2E1 était la plus élevée dans les cellules HepaRG cultivées avec du stéarate et sans insuline. Le 2ème but de notre étude était ensuite d'évaluer la cytotoxicité de l’APAP sur des cellules HepaRG présentant ou non une stéatose et une induction du CYP2E1. Des expériences avec une large gamme de concentrations d’APAP (de 1 à 20 mM) indiquaient que la perte cellulaire d'ATP et du glutathion (GSH) était presque toujours plus forte en présence de stéarate. Dans les cellules prétraitées avec le chlorméthiazole (CMZ, un inhibiteur du CYP2E1), la moindre diminution d’ATP était plus importante en présence de stéarate, avec de faibles (2,5 mM) ou de fortes (20 mM) concentrations d’APAP. Cependant, en l'absence d'insuline, la moindre chute d’ATP induite par le CMZ était significativement plus forte uniquement pour 20 mM d’APAP. Étonnamment, suite au prétraitement par le CMZ, il n'y avait pas de protection vis-à-vis de la diminution du GSH et de la formation des adduits APAP-protéines. Enfin, les concentrations du métabolite APAP-glucuronide étaient significativement augmentées en présence d'insuline. Ainsi, lorsqu’elle est étudiée dans des conditions spécifiques de culture, la lignée cellulaire HepaRG semble être un modèle intéressant de NAFLD, notamment en ce qui concerne les activités du CYP2E1 et du CYP3A4. Nos données suggèrent aussi que l’induction du CYP2E1 observée au cours des NAFLD pourrait être secondaire à l'accumulation de certains acides gras et à la présence d’une faible signalisation insulinique dans le foie. Ainsi, ce modèle cellulaire peut être utilisé pour mettre en évidence les principaux facteurs métaboliques et hormonaux favorisant hépatotoxicité de l’APAP chez les personnes obèses. Cette thèse inclut également une revue de la littérature sur l’hépatotoxicité de l’APAP dans le contexte de l’obésité et des NAFLD (Michaut et al., Liver Int 2014). / Obesity and nonalcoholic fatty liver disease (NAFLD) are able to increase the risk and the severity of hepatotoxicity induced by some xenobiotics including drugs, but the involved mechanisms are still poorly understood. For toxic compounds such as ethanol and acetaminophen (APAP), a role of hepatic cytochrome P450 2E1 (CYP2E1) is suspected since the activity of this enzyme is consistently enhanced during obesity and NAFLD. The first aim of our experimental study was to set up a cellular model of NAFLD characterized not only by triglyceride accumulation but also by higher CYP2E1 activity. To this end, differentiated human HepaRG cells were incubated during one week with stearic acid, or oleic acid, in the presence of 3 different concentrations of insulin. Cellular triglycerides and the expression of lipid-responsive genes were similar with both fatty acids. However, CYP2E1 activity was significantly increased only by stearate and this was associated with lower CYP3A4 activity, another metabolic feature reported in NAFLD. CYP2E1 activity in HepaRG cells was reduced by insulin in a concentration-dependent manner and this effect was reproduced in cultured primary human hepatocytes. Hence, the highest CYP2E1 activity was observed in HepaRG cells with stearate and without insulin. Next, the second aim of our study was to assess APAP cytotoxicity in HepaRG cells presenting or not lipid accretion and CYP2E1 induction. Experiments with a large range of APAP concentrations (1 to 20 mM) showed that the cellular loss of ATP and glutathione (GSH) was almost always stronger in the presence of stearic acid. In cells pretreated with the CYP2E1 inhibitor chlormethiazole (CMZ), recovery of cellular ATP was significantly higher in the presence of stearic acid with both low (2.5 mM) and high (20 mM) concentrations of APAP. However, in the absence of insulin, CMZ-induced ATP recovery was significantly greater only for 20 mM of APAP. Surprisingly, there was no recovery of cellular GSH and no reduction of APAP-protein adducts following CMZ pretreatment. Finally, levels of APAP-glucuronide were significantly enhanced in the presence of insulin. Hence, when studied in specific conditions of culture, the HepaRG cell line can be a valuable model of human NAFLD, especially regarding CYP2E1 and CYP3A4 activity. Our data also suggest that higher CYP2E1 activity in NAFLD could be secondary to the hepatic accumulation of some fatty acids and to the presence of low insulin signaling. This cellular model can be thus used to unveil the main metabolic and hormonal factors favoring APAP hepatotoxicity in obese individuals. This thesis also includes a review on APAP hepatotoxicity in the context of obesity and NAFLD (Michaut et al., Liver Int 2014).

Les hépatopathies métaboliques regroupent les maladies non alcooliques du foie (NAFLD) et les maladies alcooliques du foie (MAF) causées respectivement par l’obésité ou une consommation excessive d’alcool. Ces pathologies vont de la simple stéatose à des formes aggravées pouvant aller jusqu’au carcinome hépatocellulaire. D’autres facteurs que le surpoids ou l’abus d’alcool jouent un rôle dans la susceptibilité des patients à développer une NAFLD ou une MAF. Cette thèse a pour objectif de clarifier et d'étudier les mécanismes et les facteurs participant à l’installation de l’inflammation dans ces deux pathologies. Mes travaux ont porté d’une part sur le rôle de la cellule de Kupffer dans les étapes précoces de la NAFLD et d’autre part sur l’étude du microbiote intestinal comme cofacteur déclenchant de la MAF. La cellule de Kupffer lors de la stéatose, étape précoce de la NAFLD, présente une dérégulation de son homéostasie lipidique qui participe à son phénotype pro-inflammatoire et favorise l’inflammation hépatique. L’impact du fructose, largement utilisé dans notre alimentation actuelle, a été étudié et aggrave l’inflammation hépatique lors d’un régime hyperlipidique et ceci est associé à une dysbiose spécifique. Dans la MAF, une dysbiose intestinale, une diminution des Bacteroides, a été associée aux lésions hépatiques dans un modèle murin d’alcoolisation. L‘utilisation de traitements permettant de maintenir cette population à des taux élevés a corrigé cette dysbiose et protégé les animaux face aux lésions hépatiques. Ces travaux permettent d‘envisager le MI comme une cible prometteuse permettant de contrôler l’évolution des hépatopathies métaboliques vers des formes sévères. / Metabolic hepatopathies is including Non Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Liver Disease (ALD) due to an excessive consumption of alimentation or alcohol. The pathologies range from simple steatosis to aggravated forms until hepatocellular carcinoma. Other factors than overweight or alcohol abuse play a role in sensitivity of patients to develop NAFLD or ALD. The aim of this thesis is to clarify and study the mechanisms and factors that lead to the installation of inflammation in those pathologies. My work covered in part on the role of Kupffer cell in the early stages of NAFLD and secondly on the study of intestinal microbiota as a cofactor triggering the MAF.The Kupffer cell role in steatosis, the early stages of NAFLD, showed a deregulation of its lipid homeostasis involved in the pro-inflammatory phenotype and promotes liver inflammation. The impact of fructose, widely used in our current diet, was studied and worsening liver inflammation during high fat diet. This is associated with a specific dysbiosis. In ALD, intestinal dysbiosis, a decrease of Bacteroides, leading to liver damage has been established. The use of treatments to maintain this population with high levels corrected the dysbiosis and has protected animals against liver damages. Both works on the NAFLD and ALD establish MI is a promising target to control the evolution of metabolic liver diseases toward aggravated forms.

Non-alcoholic fatty liver disease (NAFLD) is a major chronic liver disease and thus a main reason for liver-related morbidities and mortality. NAFLD covers a wide range of diseases starting with steatosis and frequently progressing to non-alcoholic steatohepatitis (NASH), which is an independent predictor for the development of the hepatocellular carcinoma (HCC). Nicotinamide phosphoribosyltransferase (NAMPT), the key enzyme of the mammalian NAD salvage pathway, recycles nicotinamide to nicotinamide mononucleotide (NMN), which is further converted to nicotinamide adenine dinucleotide (NAD). NAD is not only an important redox partner but also a crucial co-substrate for NAD-dependent enzymes such as sirtuin 1 (SIRT1). Thus, NAD metabolism might be involved in the progression of NAFLD by regulating many cellular processes, such as apoptosis, de novo lipogenesis, glycolysis and gluconeogenesis, in the liver. Interestingly, tumor cells have a high NAD turnover due to their rapid proliferation and high activity of NAD-dependent enzymes. For these reasons, I hypothesized that the NAD salvage pathway is dysregulated during the progression of non-alcoholic fatty liver disease. Therefore, the first study of the present work deals with the role of the NAD salvage pathway in a diet-induced mouse model of hepatic steatosis. In mice fed a high-fat diet for 11 weeks hepatic NAMPT mRNA, protein abundance and activity as well as NAD levels were increased. Additionally, SIRT1 protein abundance was upregulated indicating a higher SIRT1 activity. This could be confirmed by detecting decreased acetylation or transcription of SIRT1 targets. For example, p53 and nuclear factor κB (NF-κB) were less acetylated demonstrating lower activity of key regulators of apoptosis and inflammation, respectively. In the second study of this thesis NAMPT activity was inhibited by applying its specific inhibitor FK866 in hepatocarcinoma cells to investigate whether or not NAMPT inhibition could be a potential novel therapeutic approach in HCC treatment. Hepatocarcinoma cells were more sensitive to NAMPT inhibition by FK866 than primary human hepatocytes, presenting a high number of apoptotic cells after FK866 treatment. FK866 induced NAD and ATP depletion which was associated with activation of the key regulator of energy metabolism 5’-AMP-activated protein kinase (AMPK) and decreased activity of its downstream target mammalian target of rapamycin (mTOR). This thesis shows that the NAD salvage pathway is involved in hepatic steatosis and HCC. During hepatic steatosis NAD metabolism is upregulated to potentially protect against adverse effects of the massive hepatic lipid accumulation. To repress the progression to NASH it might be useful to maintain the hepatic NAD levels during early disease stages by administration of NAD precursors, such as NMN. However, hepatocarcinoma cells have a higher activity of NAMPT and NAD-dependent enzymes. NAMPT inhibition by FK866 could be a potential therapeutic approach in HCC, especially due to the fact that NAD depletion is selectively induced in hepatocarcinoma cells, but not in primary human hepatocytes.